If you were a cancer patient, where would you rather be — the United States or Europe?

Natalie Grover

Reporter

LONDON — Frustrated by the lack of legislation implemented to lower soaring drug prices in the United States — a key issue that has elicited outrage …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

If you were a cancer patient, where would you rather be — the United States or Europe?

Natalie Grover

Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Nvidia-backed Achira debuts, blending AI and physics to model molecules

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

If you were a can­cer pa­tient, where would you rather be — the Unit­ed States or Eu­rope?

Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

If you were a cancer patient, where would you rather be — the United States or Europe?